Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vasopharm Raises $6.5 mill For Phase III-Ready Traumatic Brain Injury Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.


Related Content

Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts